Led · Series B · Mar 2018

Vectorious has developed a miniature wireless sensory implant and an external home unit that provide daily, ‘push-button’ left atrial pressure readings to give early physiological indication of cardiac decompensation. The system is designed for minimally invasive delivery and aims to improve CHF patient quality of life and reduce hospital readmissions by enabling optimized, physician-managed closed-loop therapy. The device measures left atrial pressure directly and transmits easy-to-access data for outpatient monitoring. According to the company the implant is safe and intended for low‑risk delivery with reduced long‑term complications. Commercial availability is currently limited—the device is not available for sale in the United States or internationally. Financially, Vectorious has secured venture and grant funding including a $9.5M Series B and earlier grants from the Israel Innovation Authority and a $2.2M Horizon 2020 award. Vectorious Medical Technologies is a Tel Aviv, Israel-based medical device company developing an implantable cardiac monitoring system for patients with congestive heart failure. The system leverages miniature sensing and wireless communications to enable daily readings of left atrial pressure. Led by founder and CEO Oren Goldstein, the company aims to advance continuous hemodynamic monitoring for CHF management. Vectorious closed a $5M financing to fund further development and clinical initiation. The company plans to use the proceeds to initiate first-in-human trials in collaboration with senior cardiologists from the U.S. and Israel.

Participated · Series E · Dec 2017

Insightec develops and commercializes the Exablate Prime focused-ultrasound platform to provide incisionless, immediate tremor treatment for patients with medication-refractory essential tremor and Parkinson’s disease. The Exablate Prime platform is FDA approved for those indications. The company reports over 160 systems installed worldwide and its technology has been used in nearly 20,000 commercial applications. Led by CEO Maurice R Ferré, Insightec is based in Haifa, Israel and Miami, FL, and also has offices in Dallas, Shanghai, and Tokyo. The company raised $150M in equity financing and intends to use the funds to expand operations and advance its development efforts. Insightec develops and commercializes the Exablate Neuro platform, which uses MRI‑guided acoustic energy to deliver incisionless neurosurgery for medication‑refractory Essential Tremor and Parkinson’s Disease. The company is led by CEO Maurice R. Ferré and is conducting research and clinical trials to expand applications into neuro‑oncology and other neurological conditions in partnership with academic and medical institutions. Insightec intends to drive broader adoption of its incisionless treatments while continuing to advance innovation and clinical research. Financially, the company signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund, receiving $100 million at closing. The facility is interest‑only for five years and matures on August 31, 2027, with an additional $100 million potentially available in tranches through 2024. The company operates from Haifa, Israel and Miami, Florida, and has additional offices in Dallas, Shanghai, and Tokyo. Insightec makes a magnetic resonance–guided focused ultrasound device that ablates the thalamus using high‑intensity sound waves to reduce hand tremors without an incision. The device is approved by the FDA to treat essential tremor in patients unresponsive to medication and has expanded approval for tremor‑dominant Parkinson’s disease. The procedure is unilateral and currently can be performed on only one side of the brain, typically addressing the dominant hand. The company has redirected focus toward neurology after earlier work on other indications, such as uterine fibroids, saw limited hospital traction. Insightec has sold its technology to more than 65 health systems worldwide, and a study of 76 essential tremor patients funded in part by the company reported 58% of patients had at least a 50% improvement in hand tremor and function at three years. Its global headquarters is in Israel and its U.S. headquarters is in Miami. Insightec is a commercial-stage medical device company that develops MRI-guided focused ultrasound platforms for non-invasive surgical therapies. Its therapy platforms, Exablate and Exablate Neuro, are proven technologies with clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. Led by Maurice R. Ferré, MD, CEO and Chairman of the Board, the company brings solutions to patients by collaborating with physicians, medical institutions, academic researchers and regulatory bodies worldwide. Insightec is based in Haifa, Israel, and Miami, Florida, and also maintains offices in Dallas, Tokyo and Shanghai. The company intends to use new funds to further commercialize its approved indications and to continue research into Parkinson’s disease, Alzheimer’s disease and brain tumors. It recently raised $150M in a Series E pre-IPO financing. Insightec develops a non-invasive therapy platform based on Magnetic Resonance-guided Focused Ultrasound (MRgFUS). Founded in 1999 and based in Dallas, Texas and Haifa, Israel, the company’s technology is already used by physicians in more than 120 medical facilities worldwide. Its indications are expanding across neurosurgery, oncology and gynecology. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors. Insightec recently secured $22M in a Series D financing. Leadership will transition to newly appointed CEO Dr. Maurice R. Ferré, while founder and former CEO Dr. Kobi Vortman will move to the board and continue to drive strategy and the product roadmap.